<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493269</url>
  </required_header>
  <id_info>
    <org_study_id>18385</org_study_id>
    <secondary_id>2017-001817-10</secondary_id>
    <nct_id>NCT03493269</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Rheumatoid Arthritis or Psoriasis Over an Extended Treatment Duration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male
      subjects (Part 1) and in patients with RA or psoriasis (Part 2) To assess the pharmacokinetic
      (PK) properties of total BAY 1834845 in plasma after oral multiple doses of BAY1834845 in
      healthy male subjects (Part 1) and patients with RA or psoriasis (Part 2)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">August 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 47 days</time_frame>
    <description>Part 1 in healthy male subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 47 days</time_frame>
    <description>Part 1 in healthy male subject</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 73 days</time_frame>
    <description>Part 2: Patients with RA or psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Approximately 73 days</time_frame>
    <description>Part 2: Patients with RA or psoriasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md of BAY1834845</measure>
    <time_frame>Part 1 - Period 1: Day 1 to 12, Day 13, 15, 17</time_frame>
    <description>Part 1 AUC(0-24)md: AUC from zero to 24 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md of BAY1834845</measure>
    <time_frame>Part 1 - Period 2: Day 1, 2, 3, 5, 6, 8</time_frame>
    <description>Part 1 AUC(0-12)md:AUC from zero to 12 hours after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md of BAY1834845</measure>
    <time_frame>Part 1: Period 1: Day 1 to 12, Day 13, 15, 17;Period 2: Day 1, 2, 3, 5, 6, 8</time_frame>
    <description>Part 1 Cmax,md:Cmax(Maximum observed drug concentration, directly taken from analytical data) after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav of BAY1834845</measure>
    <time_frame>Part 1: Period 1: At Day 1 to 12, Day 13, 15, 17;Period 2: Day 1, 2, 3, 5, 6, 8</time_frame>
    <description>Part 1 Cav:Average concentration within a dosing interval after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24)md of BAY1834845</measure>
    <time_frame>Part 2: At Day 1, 2, 7, 14, 21, 28, 35, one day between day 35 and 42, Day 42</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-12)md of BAY1834845</measure>
    <time_frame>Part 2: At Day 1, 2, 7, 14, 21, 28, 35, one day between day 35 and 42, Day 42</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,md of BAY1834845</measure>
    <time_frame>Part 2: At Day 1, 2, 7, 14, 21, 28, 35, one day between day 35 and 42, Day 42</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cav of BAY1834845</measure>
    <time_frame>Part 2: At Day 1, 2, 7, 14, 21, 28, 35, one day between day 35 and 42, Day 42</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 4 dose groups with ascending dose levels in healthy male subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Matching placebo in healthy male subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose A of BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: This dose level will be adminstered in female and male patients with RA or psoriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose B of BAY1834845</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: This dose level will be adminstered in female and male patients with RA or psoriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: The placebo will be adminstered in female and male patients with RA or psoriasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1834845</intervention_name>
    <description>Part 1: Orally administered Multiple ascending doses. The treatment will last 10 consecutive days (treatment period 1) and 1 day (treatment period 2).
Part 2: Administered dose will be decided based on the results of Part 1, The treatment will last 42 consecutive days.</description>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_label>High dose A of BAY1834845</arm_group_label>
    <arm_group_label>Low dose B of BAY1834845</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Part 1 and Part 2: Orally administered in Part 1 and Part 2.</description>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Part 1: Orally administered 1mg as a single dose.</description>
    <arm_group_label>BAY1834845</arm_group_label>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1 (healthy male subjects)

          -  Healthy male subjects, 18 to 50 years of age (inclusive), and in good health as
             determined by medical history, physical examination, vital signs, electrocardiogram
             (ECG), and laboratory tests at screening

          -  Body mass index (BMI) above or equal to 18.5 and lower or equal to 30 kg/m2 (BMI =
             body weight (kg) / [height (m)]2 and a body weight above or equal 50 kg Part 2
             (patients with RA or psoriasis)

          -  Male patients, 18 to 65 years of age (inclusive) or female, postmenopausal patients,
             45 to 65 years of age (inclusive).

          -  Body mass index above or equal to 18.5 and lower or equal to 32 kg/m2 and a body
             weight above or equal 50 kg Rheumatoid arthritis

          -  A documented diagnosis of RA, obtained at least 6 months prior to study drug
             administration, fulfilling the American College of Rheumatology/ European League
             Against Rheumatism (2010 ACR/EULAR) classification criteria.

          -  Concomitant treatment with methotrexate for at least 12 weeks, with a stable dose for
             at least 4 weeks prior to randomization Psoriasis

          -  A documented diagnosis of psoriasis, obtained at least 6 months prior to study drug
             administration with mild to moderate plaque psoriasis, defined by involved body
             surface area (BSA) above or equal 3%, Psoriasis Area and Severity Index (PASI) score
             of above or equal 5, and Physician's Global Assessment (PGA) score of above or equal 2

        Exclusion Criteria:

          -  History of hypersensitivity to any of the components of the study drug

          -  Any clinically relevant abnormal findings in safety laboratory parameters and ECG

          -  History of tuberculosis (TB) or active or latent tuberculosis

          -  Receipt of live or attenuated vaccine 90 days prior to the first dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis;</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

